Haemophilia Studies

The Haemophilia Department at St James’s hospital, has a long established research program over the last 7 years. The CRF in conjunction with the National Coagulation Centre runs a number of both investigator-led and industry centred drug trials in Haemophilia. In Fact this area of medicine has seen dramatic changes over the last number of years with the introduction of gene therapies within a research setting. We are the only centre in Ireland to have conducted gene therapy studies in haemophilia.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
BH30071- Haemophilia AA randomized, multicenter, open-label, Phase 3 clinical trial to evaluate the efficacy, safety and pharmacokinetics of prophylaxis in hemophilia A patients without inhibitorsClinical TrialRocheCommercial: Industry
FIX-GTA Phase I/II, open label, multicentre, ascending, single dose, safety study of a novel adeno-associated viral vector (FLT180a) in patients with Haemophilia BClinical TrialCommercial: Industry
iPATHThe Irish Personalized Approach to the treatment of Haemophilia (iPATH): An investigation of the relationship between physical health, physical activity and bleeding phenotype in adults with haemophiliaObservational-non invasiveNon-commercial: Academic
Hope-BPhase III trial of AMT-061 in subjects with severe or moderately severe hemophilia B.Clinical Trial UniqureCommercial: Industry
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
PERSONALPERSONALising Factor VIII prophylaxis regimens: Efficacy of standard versus pharmacokinetically based regimens in adult patients with severe Haemophilia A (PERSONAL trial)Clinical TrialCommercial: Industry
Dabigatran ReversalA phase 3 case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab BI 655075 in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or proceduresClinical TrialCommercial: Industry
BAX326 ContinuationBAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Sever (FIX level < 1 %) or moderately severe (FIX level 1-2%) Hemophilia B- A Continuation StudyClinical TrialCommercial: Industry